The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 15, 2021

Filed:

Oct. 01, 2018
Applicants:

Promab Biotechnologies, Inc., Richmond, CA (US);

Forevertek Biotechnology Co., Ltd., Hunan, CN;

Inventors:

Lijun Wu, Albany, CA (US);

Vita Golubovskaya, Richmond, CA (US);

Martyn Lewis, Danville, CA (US);

Hua Zhou, Hercules, CA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/43 (2013.01);
Abstract

The present invention provides chimeric antigen receptor (CAR)-T cells modified to express a CAR fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising Vand V, wherein scFv has an activity against a tumor antigen CD19, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the fusion protein further comprises a FLAG tag N-terminus to scFv, C-terminus to scFv, or between Vand V. Using CD19-FLAG CAR-T cells instead of CD19 CAR-T cells, cytokine levels (Interferon-γ, IL-2 and IL6) caused by infused CAR-T cells are reduced.


Find Patent Forward Citations

Loading…